Independent intelligence for the laboratory world

FDA Authorizes Roche cobas pro i 601 for Automated Gabapentin Mass Spectrometry

Rocheโ€™s cobas pro i 601 platform and Ionify Gabapentin assay received FDA De Novo authorization for automated clinical mass spectrometry.

Roche cobas i 601 mass spectrometry analyzer for automated clinical laboratory testing. Image courtesy of Roche.

Press release summary

BASEL, Switzerland โ€” Roche said Nov. 16 that the U.S. Food and Drug Administration granted De Novo authorization for the cobas pro i 601 platform with the Ionify Gabapentin assay, components of the companyโ€™s automated clinical mass spectrometry system.

The assay adds therapeutic drug monitoring for gabapentin to a U.S. menu that includes total 25-hydroxy vitamin D and steroid hormone tests. Roche designed the system to integrate mass spectrometry into a standardized core-laboratory workflow, including automated sample preparation, analysis and result processing.

The authorization also includes a predetermined change control plan. Roche said the plan could support the addition of as many as 22 Ionify assays when specified FDA requirements are met. Those assays are not yet available, and each future addition remains subject to the authorized planโ€™s conditions.

Why it matters: Clinical mass spectrometry often requires specialized staff and labor-intensive preparation. An authorized automated platform could help more routine laboratories adopt the technology for therapeutic drug monitoring while improving standardization. Laboratories evaluating the system should still review assay-specific performance, staffing, interfaces, quality control, maintenance and local regulatory status.

Read Rocheโ€™s original Nov. 16 release.

Join the Discussion

Share your experience or ask a question about this article. Please keep comments relevant and respectful.

Leave a Reply

Your email address will not be published. Required fields are marked *